{"id":58609,"date":"2024-02-28T05:19:38","date_gmt":"2024-02-28T05:19:38","guid":{"rendered":"https:\/\/medsname.com\/oliza\/"},"modified":"2026-04-30T10:24:11","modified_gmt":"2026-04-30T10:24:11","slug":"oliza","status":"publish","type":"product","link":"https:\/\/medsbase.com\/hu\/product\/oliza\/","title":{"rendered":"Oliza"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Gyors v\u00e1lasz<\/h3>\n

Oliza (Olanzapine 2.5 \/ 5 \/ 10 mg) is an atypical antipsychotic for schizophrenia, bipolar mania and maintenance, treatment-resistant depression (with fluoxetine), and acute agitation. The most robust antipsychotic effect of the atypicals \u2014 but the heaviest metabolic burden.<\/p>\n<\/div>\n

\nMit kapsz a MedsBase-n\u00e1l:<\/strong> WHO-GMP min\u0151s\u00edt\u00e9s\u0171 gy\u00e1rt\u00f3 \u00b7 Diszkr\u00e9t csomagol\u00e1s \u00b7 Vil\u00e1gszerte sz\u00e1ll\u00edt\u00e1s \u00b7 1.400+ hiteles\u00edtett v\u00e1s\u00e1rl\u00f3i v\u00e9lem\u00e9ny<\/a>\n<\/div>\n

\ud83d\udce6 Minden rendel\u00e9st fedez a \u00dajrak\u00fcld\u00e9si Garancia<\/strong><\/a> \u2014 ha a csomagod nem \u00e9rkezik meg 20 munkanapon bel\u00fcl, \u00fajrak\u00fcldj\u00fck.<\/p>\n

Mi\u00e9rt rendelj a MedsBase-r\u00f3l<\/h3>\n

Oliza at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our \u00dajrak\u00fcld\u00e9si Garancia<\/a> \u2014 20 \u00fczleti napos \u00e9rkez\u00e9si ablak vagy ingyenes \u00fajrasz\u00e1ll\u00edt\u00e1s \u2014 \u00e9s jogosult a mi h\u0171s\u00e9gprogramunkra<\/a>. .<\/p>\n

What Oliza is and how it works<\/h2>\n

Oliza is an olanzapine tablet supplied by Cipla. Available strengths: 2.5 \/ 5 \/ 10 mg<\/strong>. Olanzapine is a thienobenzodiazepine atypical antipsychotic with strong D2 antagonism, strong 5-HT2A antagonism, and substantial H1 (sedation, weight gain), M1 (anticholinergic), and \u03b11 (orthostasis) blockade. The H1+M1 receptor profile is responsible both for its calming\/sedative effect (useful in acute agitation) and for its metabolic burden.<\/p>\n

What Agoprex is and how it works<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Agoprex is a 25 mg agomelatine tablet supplied by Sun Pharma. Agomelatine is mechanistically unique among antidepressants: it acts as an agonist at melatonin MT1 and MT2 receptors and an antagonist at 5-HT2C serotonin receptors. The dual mechanism resynchronises disrupted circadian rhythms (a feature of major depression) while indirectly increasing dopamine and noradrenaline release in the frontal cortex.<\/th>\nAgomelatine has no SERT activity, no anticholinergic effects, and no histaminergic effects \u2014 explaining its very different side-effect profile from SSRIs and TCAs.<\/th>\nIndications and dosing<\/th>\nIndication<\/th>\n<\/tr>\n<\/thead>\n
Skizofr\u00e9nia (feln\u0151tt)<\/td>\n5\u201310 mg OD<\/td>\n10\u201320 mg OD<\/td>\n20 mg<\/td>\n<\/tr>\n
Skizofr\u00e9nia (serd\u00fcl\u0151 \u2265 13 \u00e9ves)<\/td>\n2.5\u20135 mg OD<\/td>\n10 mg\/nap<\/td>\n20 mg<\/td>\n<\/tr>\n
Bipol\u00e1ris m\u00e1ni\u00e1s epiz\u00f3d (feln\u0151tt)<\/td>\n10\u201315 mg\/nap<\/td>\n10\u201320 mg OD<\/td>\n20 mg<\/td>\n<\/tr>\n
Acute agitation (IM)<\/td>\n10 mg IM<\/td>\n\u2014<\/td>\n3 doses\/24h<\/td>\n<\/tr>\n
Treatment-resistant depression (with fluoxetine)<\/td>\n5 mg + 20 mg fluoxetine<\/td>\n5\u201318 mg<\/td>\n18 mg<\/td>\n<\/tr>\n
Older adults<\/td>\n2.5\u20135 mg OD<\/td>\n5\u201310 mg OD<\/td>\ntolerancia alapj\u00e1n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Fontos biztons\u00e1gi megfontol\u00e1sok<\/h2>\n
\nFDA fekete doboz \u2014 demenci\u00e1val \u00f6sszef\u00fcgg\u0151 pszich\u00f3zis<\/strong><\/p>\n

Az \u00f6sszes at\u00edpusos antipszichotikum hordoz egy FDA fekete doboz figyelmeztet\u00e9st a megn\u00f6vekedett hal\u00e1loz\u00e1si kock\u00e1zat miatt (f\u0151leg cardiovascularis \u00e9s fert\u0151z\u00e9ses okokb\u00f3l), amikor id\u0151s, demenci\u00e1ban szenved\u0151 betegek viselked\u00e9szavarainak kezel\u00e9s\u00e9re haszn\u00e1lj\u00e1k. Az at\u00edpusos antipszichotikumok nincsenek j\u00f3v\u00e1hagyva demenci\u00e1val \u00f6sszef\u00fcgg\u0151 pszich\u00f3zis vagy agit\u00e1ci\u00f3 kezel\u00e9s\u00e9re<\/strong>. Haszn\u00e1latuk ebben a popul\u00e1ci\u00f3ban off-label, utols\u00f3 lehet\u0151s\u00e9g, id\u0151korl\u00e1tozott, \u00e9s kifejezett kock\u00e1zat-haszon besz\u00e9lget\u00e9st ig\u00e9nyel.<\/p>\n<\/div>\n

\nHeaviest metabolic burden of the atypicals<\/strong><\/p>\n

Olanzapine produces the most weight gain (typically 4\u201310 kg in the first 6 months, sometimes far more), the most insulin resistance, and the most lipid disturbance of any commonly-used antipsychotic. Patients can develop type 2 diabetes within months of initiation. Mandatory monitoring: weight at every visit; fasting glucose \/ HbA1c and fasting lipids at baseline, 12 weeks, then 6-monthly.<\/strong> Counsel about diet and exercise from initiation.<\/p>\n<\/div>\n

\nSedation and anticholinergic burden<\/strong><\/p>\n

Strong sedation in the first 1\u20132 weeks. Anticholinergic effects (dry mouth, constipation, urinary hesitancy) are universal. Both lessen but do not disappear.<\/p>\n<\/div>\n

\nOlanzapine + benzodiazepine IM \u2014 caution<\/strong><\/p>\n

Combining IM olanzapine with parenteral benzodiazepines has produced cases of severe hypotension, respiratory depression, and death. If both are clinically necessary in acute agitation, separate by \u2265 1 hour and monitor closely.<\/p>\n<\/div>\n

Gyakori mell\u00e9khat\u00e1sok<\/h2>\n